|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-1-9
|
|
pubmed:abstractText |
The success of beta-blocking agents in clinical trials of heart failure (HF) has led to a widespread call for their increased use, which assumes these agents will perform as well in the usual care setting. Given the traditional contraindication of the use of beta-blocking agents in HF, and their perception as difficult to use in HF, observing how they perform in the usual care setting could be critical in accelerating their widespread application. Carvedilol is the only beta-blocking agent currently approved in the United States for use in HF.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1071-9164
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
264-71
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10997754-Adrenergic beta-Antagonists,
pubmed-meshheading:10997754-Antihypertensive Agents,
pubmed-meshheading:10997754-Carbazoles,
pubmed-meshheading:10997754-Clinical Trials as Topic,
pubmed-meshheading:10997754-Female,
pubmed-meshheading:10997754-Heart Failure,
pubmed-meshheading:10997754-Humans,
pubmed-meshheading:10997754-Male,
pubmed-meshheading:10997754-Propanolamines,
pubmed-meshheading:10997754-Registries,
pubmed-meshheading:10997754-United States,
pubmed-meshheading:10997754-Vasodilator Agents
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.
|
|
pubmed:affiliation |
Mount Sinai School of Medicine and Cornell University, Weill Medical College, New York, New York, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
